Arrowhead Pharmaceuticals Reports Strong Q3 2026 on REDEMPLO Growth and Pipeline Progress
Event summary
- REDEMPLO prescription volume doubled in Q3, with over 400 unique practitioners prescribing the drug.
- Arrowhead acquired a priority review voucher for plozasiran, potentially accelerating FDA approval for severe hypertriglyceridemia (sHTG).
- The company announced positive topline results from SHASTA-3 and SHASTA-4 studies, showing 79% and 81% triglyceride reductions respectively.
- Arrowhead signed a $25 million upfront license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, with potential milestone payments up to $975 million.
The big picture
Arrowhead Pharmaceuticals is capitalizing on the commercial success of REDEMPLO while advancing its pipeline through strategic partnerships and positive clinical data. The company's focus on RNAi therapeutics positions it in a growing sector of precision medicine, with significant potential for both near-term revenue growth and long-term pipeline expansion.
What we're watching
- Commercial Momentum
- How Arrowhead will sustain REDEMPLO's prescription growth and payer coverage expansion.
- Regulatory Pathway
- Whether the priority review voucher will accelerate plozasiran's approval for sHTG.
- Pipeline Execution
- The pace at which Arrowhead advances its diverse RNAi therapeutic pipeline, particularly ARO-PNPLA3 under the Madrigal agreement.
Related topics